Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp

Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple in 2026, as patient access to the sickle cell disease and beta thalassemia gene therapy grows.